时迈药业
  • About us
    Company overview our culture milestones leadership contact US
  • Science & Pipeline
    Technology platform pipeline
  • partnering
    Partners partnering strategy
  • Join us
  • News
CN
  • EN
    CN
  • Home
  • about us
    Company overview our culture milestones leadership contact US
  • Science & Pipeline
    Technology platform pipeline
  • partnering
    Partners partnering strategy
  • Join us
  • News
  • Join us
网站地图
Home
Home
About Us
Company overview
our culture
milestones
leadership
contact US
Science & Pipeline
Technology platform
pipeline
partnering
Partners
partnering strategy
News
  • Company news
    Shimai Pharma Presents DNV3 (LAG-3 Antibody) Combination Therapy Results for Melanoma at ASCO 2025 Annual Meeting Shimai Pharma Presents SMET12 (EGFR×CD3 Bispecific Antibody) Combination Therapy Results for Advanced NSCLC at ASCO 2025 Annual Meeting CentryMed to Present Clinical Data on SMET12 and DNV3 at 2025 ASCO Annual Meeting CentryMed’s Groundbreaking Enzyme-Controlled TCE Technology: Recombinant Human Anti-EGFR-CD3 Bispecific Antibody CMDE005 Receives FDA IND Clearance International Endorsement, Global Leadership | GPC3×CD3 Bispecific Antibody CMD011 Receives FDA IND Clearance
  • science highlights
Join Us
join us
时迈药业
CHINA
U.S.A
  • 时迈药业
    Address:2008 Huachuang Edifice, Jianye RD No.511, Binjiang, Hangzhou
    时迈药业
    Tel:+0571-87314597
    时迈药业
    Mail : HR@centrymed.com
    时迈药业
    时迈药业
  • 时迈药业
    Address:5107 Pegasus Court, Suite L Frederick, MD 21704, U.S.A
    时迈药业
    Tel:+0571-87314597
    时迈药业
    Mail : HR@centrymed.com
    时迈药业
    时迈药业
  • about us
    Company overview our culture milestones leadership contact US
  • Science & Pipeline
    Technology platform pipeline
  • partnering
    Partners partnering strategy
  • News
  • Join us
ICP NO.18020885-1
|
33010802013098
Copyright2025 Zhejiang Shimai Pharmaceutical Co.,Ltd DESIGNBY:5ISJ.COM
Sitemap
Powered By : HANSUN
时迈药业
: mailbox
时迈药业
: Office System